Veeva Systems’s (NYSE:VEEV) Q2 CY2026 Sales Top Estimates, Stock Soars

Veeva Systems (VEEV) reported Q2 CY2026 revenue of $928M, up 17.6% YoY, beating estimates. Guidance for Q3 was also above expectations. Non-GAAP EPS was $2.35, 5.8% higher than consensus. CEO Peter Gassner highlighted AI-driven growth in Vault CRM and Veeva Falcon. The stock rose 8.9% post-earnings.

Original reporting
Published Aug 26, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Veeva Systems’s (NYSE:VEEV) Q2 CY2026 Sales Top Estimates, Stock Soars — source image
Decision brief

The 30-second read

$VEEVBullishHigh
01

Why it matters

The earnings beat and raised guidance reinforce Veeva's growth narrative, likely supporting further price appreciation.

02

Market read

Strong earnings and guidance lift Veeva's stock and may boost related sector sentiment.

03

What to watch

Future guidance may be challenged by slower pharma spending or competitive pressure.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Veeva Systems is a leading provider of cloud software for life‑sciences companies, known for its CRM and data platforms.

Company-level read

Ticker impact

$VEEVBullishHigh confidence
Context

Veeva Systems reported Q2 CY2026 revenue of $928M, beating estimates and raised Q3 guidance, causing the stock to jump 8.9% after hours.

Expected impact

potential further 5‑10% rally in the next few trading sessions

Evidence & confidence

Strong top‑line growth, beat, and guidance above consensus drive bullish sentiment.

Market effects

Life‑sciences cloud software sector may see broader optimism from Veeva's beat.

U.S. tech and healthcare indices could receive a modest lift.

Limited to investors tracking cloud‑software providers.

Counterpoint

Valuation may already price in growth; any slowdown could trigger a pullback.

Key entities

  • Peter Gassner

    Provided commentary on AI-driven growth and product acceleration.

Related articles

$NVDAHighAI 8/10

Stocks making the biggest moves after hours: Nvidia, Salesforce, CrowdStrike, Urban Outfitters and more

Nvidia, Salesforce, Okta, Agilent, CrowdStrike, Everpure, Veeva, Urban Outfitters, and Synopsys reported earnings. Nvidia, Salesforce, Okta, Agilent, CrowdStrike, Everpure, and Veeva exceeded expectations, while Urban Outfitters met estimates and Synopsys fell. Nvidia reported $2.22 EPS and $96.22B revenue, raising Q3 guidance to $108B. Salesforce reported $11.35B revenue and $5.90 EPS. Okta raised full-year guidance. Synopsys raised annual revenue and profit forecasts but shares fell 2%.

$VEEVHighAI 9/10

Why is Veeva Systems stock surging today?

Veeva Systems (VEEV) stock rose 8.1% after reporting fiscal Q2 2027 results that exceeded expectations, with subscription revenues of $766.8M, up 16% YoY. The company raised full-year guidance, and analysts increased the price target to $314.71. Biogen and Regeneron announced commitments to Veeva's Vault CRM platform, driving demand for its AI-powered commercial suite. The broader market had minimal impact on Veeva's after-hours move, which was driven by company-specific catalysts.

$VEEVMedAI 8/10

Veeva Announces Fiscal 2027 Second Quarter Results

Veeva Systems reported Q2 2027 results with total revenue of $928.0M, up 18% YoY, and subscription revenue of $766.8M, up 16% YoY. Operating income increased 40% YoY to $275.0M. The company raised its full-year guidance and highlighted growth in AI-driven products like Vault CRM and Falcon. CEO Peter Gassner emphasized AI's role in driving efficiency in the life sciences industry.

$VEEVLow

Veeva Systems Taps Dan Rizzo to Lead Global Sales as Veteran Executive Departs — BigGo Finance

Veeva Systems (VEEV) appointed Dan Rizzo as executive vice president of sales, consulting, and services, replacing Thomas D. Schwenger, who is leaving to become CEO at a partner company. The change comes as Veeva secures a global deployment deal with Eli Lilly, reinforcing its position in the life sciences industry. Investors will watch Veeva's upcoming quarterly results for insights on sales pipeline, customer retention, and suite adoption rates. The company projects revenue of $4.7B and earnin